

TABLE OF CONTENTS

ACKNOWLEDGMENTS.....	iii
TABLE OF CONTENTS.....	iv
LIST OF ABBREVIATIONS.....	viii
THESIS SUMMARY.....	1
RÉSUMÉ DE THÈSE.....	2
1. GENERAL INTRODUCTION.....	3
1.1. Prostate Cancer.....	3
1.1.1. Epidemiology.....	3
1.1.2. Diagnosis.....	5
1.1.3. Classification and Staging.....	6
1.2. Localized PCa.....	10
1.2.1. Primary treatment with radical intent.....	10
1.2.2. Persistent residual disease post-RP.....	10
1.3. Relapse after curative treatments.....	11
1.4. Imaging techniques at BCR.....	12
1.4.1. Conventional Imaging Techniques (CIT).....	12
1.4.1.1. Bone scintigraphy.....	12
1.4.1.2. Computed Tomography.....	13

1.4.1.3.	Magnetic resonance imaging (MRI).....	13
1.4.2.	Molecular Imaging with PET/CT	14
1.4.2.1.	¹⁸ F-FDG PET/CT.....	14
1.4.2.2.	¹¹ C-Choline or ¹⁸ F-Choline PET/CT	15
1.4.2.3.	¹⁸ F-NaF or Fluoride PET/CT	16
1.4.2.4.	⁶⁸ F-FACBC or Fluciclovine PET/CT	16
1.4.3.	PSMA-ligand PET/CT	17
1.4.3.1.	What is PSMA?	17
1.4.3.2.	PSMA radiotracer evolution and development	18
1.4.3.3.	⁶⁸ Ga-PSMA-11 PET/CT	20
1.4.3.3.1.	Uptake and biodistribution.....	20
1.4.3.3.2.	Comparison with other imaging techniques	22
1.5.	Oligometastatic disease	23
1.6.	Metastatic Prostate Cancer	27
1.6.1.	Hormone-sensitive prostate cancer (mHSPC).....	27
1.6.2.	Castration-resistant prostate cancer (CRPC).....	28
1.6.3.	Follow-up and imaging during treatment.....	29
3.	Justification of the thesis	31
3.1.	Objectives	32

3.2.	Hypothesis	32
3.3.	Methods	33
4.	STUDIES	34
4.1.	Biochemical Recurrence Detection	34
4.1.1.	Study 1: Clinical impact of ⁶⁸ Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach	34
4.1.2.	Study 2: Oligometastatic Disease Detection with ⁶⁸ Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact	42
4.1.3.	Study 3: ⁶⁸ Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy.....	57
4.2.	Response assessment with ⁶⁸ Ga-PSMA PET/CT	66
4.2.1.	Study 4: Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant PCa patients.....	66
4.2.2.	Study 5: ⁶⁸ Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.....	77
5.	Main results of this thesis	105
5.1.	Biochemical recurrence detection.....	105
5.2.	Response Assessment	106
6.	General discussion.....	107

6.1. Recurrence detection.....	107
6.2. Response Assessment	115
7. Future perspectives.....	125
8. General Conclusion	127
9. References	128